Hualan Biological Vaccine Inc. (SHE:301207)

China · Delayed Price · Currency is CNY

17.67

+0.29 (1.67%)

Jul 31, 2026, 3:05 PM CST

-7.87% (1Y)

Market Cap	10.51B -7.9%
Revenue (ttm)	1.20B +7.8%
Net Income	187.51M -6.1%
EPS	0.32 -5.8%
Shares Out	595.00M
PE Ratio	56.08
Forward PE	49.08
Dividend	1.60 (9.05%)
Ex-Dividend Date	Jun 15, 2026

Volume	4,612,402
Open	17.05
Previous Close	17.38
Day's Range	17.05 - 17.67
52-Week Range	15.43 - 27.88
Beta	0.63
Analysts	Strong Buy
Price Target	26.84 (+51.9%)
Earnings Date	Aug 29, 2026

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company’s main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-drie... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2005

Employees 708

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301207

Full Company Profile

Financial Performance

In 2025, Hualan Biological Vaccine's revenue was 1.20 billion, an increase of 6.62% compared to the previous year's 1.13 billion. Earnings were 182.92 million, a decrease of -10.99%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 301207 stock is "Strong Buy." The 12-month stock price target is ¥26.84, which is an increase of 51.90% from the latest price.

Price Target

¥26.84

(51.90% upside)

Analyst Consensus: Strong Buy

Stock Forecasts